Member Info for elrico

bigpunt,

Ah, you make sense now. I am glad I asked.

I think you make a very important point. SM appears to be the preferred medium for marketing. But not everyone uses SM. However, they have used two may even three advertorials in the national press. So, at least two-dimensional. :)

I guess the use of SM allows for ease of tracking. Perhaps as funds allow, they may explore other opportunities. With Acne, I doubt they will explore outside SM much because of the demographic. However, psoriasis is an altogether proposition.

bigpunt,

A couple of questions, if I may. One outstanding and "I do disagree about building sales." I am unsure what you disagree with me on.

And

You say," he (SA) may be dynamic, but it is currently only in one dimension."

bigpunt,

OPTI and SBTX may produce very different products for different healthcare conditions. You opened the door by expressing your disappointment in AxisBiotix sales. I merely provided a reasonable comparison; after all, OPTI has c12 products across its pre/probiotic range. Moreover, a 4-year head start. The estimated sales are c$50k pm rounded up. AxisBiotix is more than double this figure in 9 months for UK and c4-months for the USA. The sales, marketing and influences have only been in place for c4-months. The sales are well ahead of where SOH anticipated for 12 months and was after March, so a good 9 months earlier, and will a rising MoM trend. However, the caveat is it remains very early to get too excited, even with retention rates as high as 80%, which will, of course, fluctuate as will sales over a period.

There is no race to build sales. Instead, the key is building on what the Company has started—managing the funds frugally by spending them wisely. Of course, any fool can throw money marketing, but there is no guarantee it will have the desired impact on sales.

bigpunt,

You say," he (SA) may be dynamic, but it is currently only in one dimension."

I am unsure what you mean by this. I think you may be forced too much attention to the AxisBiotix probiotic, which is a new concept/strategy for D2C sales. SBTX was never set up for this strategy. SBTX was initially set up as B2B but had the options with the Croda partnership to develop D2C via its own branded goods. The new topical cream may offer another product dimension, as will the next probiotic, thought to target Acne.

I would disagree with your view that AxisBiotix sales are slow. Both the UK and USA have already surpassed OPTI's whole portfolio. The OPTI online store has a four-year headstart, and yet, seemingly with little marketing spend and retention rates at c80%, there is early evidence the strategy is starting to pay dividends. Yes, it is still early days, just 9-months. AxisBiotix is not a seasonal or lifestyle choice product, and it has the potential to be a product for life.

Acne is a much bigger market.
Oral care is another dimension, with a potentially huge market, perhaps even more significant than anti-ageing cosmetics.

We are yet to learn what other dimensions Croda/Sederma will offer. But, I strongly suspect we will know just how vital Croda/Sederma will be. And the best bit...whatever range of products has SBTX IP as the intel inside, there is no capital outlay from SBTX - it is money for old rope.

Bigpunt,

It is perhaps best to sum Stuart up as a dynamic get stuff done and not sit around using COVID as an excuse. For example, the original plan for psoriasis was to put it through its scientific paces with a clinical trial. COVID prevented this because all available lab space was utilised to combat COVID. Stuart opted for the consumer study route, which proved highly successful, and saved a large chunk of cash, meaning SBTX would have needed to raise additional funds for the clinical study. Instead, AxisBiotix is now generating meaningful revenues, c2-3 years ahead of schedule. OK, AxisBiotix cannot as yet make specific claims. Therefore, marketing has to be more imaginative. However, it is working, with sales increasing, retention rates increasing, and positive consumer feedback also growing. A new topical cream seems likely very soon, and I suspect Geof is busy doing what he does best and also using his expansive contact across the industry.

I have a strong hunch Stuart has a few free-range eggs at the ready for the doubters and the abusers. I have learned the hard way never to mess with a Geordie. I know their mentality well.

Before too long, expect several skincare probiotics, topical creams, and perhaps dandruff products. Meanwhile, Croda/Sederma and clients will launch a range of cosmetic products for a range of skincare options, not just anti-ageing.

We haven't even touched on the other four pillars.

Mad,

TBF, I'm aligned with your view. The SBTX board are, as we know, frugal with our cash and looks to use it wisely. IMHO, quite a few investors forget we are at least two years ahead of schedule in terms of having a consumer product. Unless my old grey deceives me, the original plan before COVID was a clinical trial, which is both costly and lengthy. It is likely a fundraiser event would have been needed for the clinal trial to ensure there be a safe buffer. Off the top of my head, a clinical trial would cost somewhere in the region of £3m. Assume this is close, hardly dilutive. Again, assuming the clinical trial was for psoriasis, the benefit would be specific marketing claims. However, even though it is very early, the estimated sale figures are outperforming what SOH had anticipated by a long way after just nine months. Would a science validation improve the estimated sales figure by much? I've no idea. I suspect they may.

IMHO, I don't see SBTX changing their strategy at this stage; therefore, a fundraiser is unlikely. Moreover, assuming the oral project proves commercially viable, I think it comes with a milestone payment upfront (again - subject to my old grey remembering correctly). Of course, we have no clue how much any such advance would be... six or seven figures or a mere five?

Don't forget; it is almost certain some revenues are being received from the Croda/Sederma, and royalty payments are expected before year-end.

I tucked away a cheeky SB this afternoon, prompted by the drop. :)

Toyin,

The AxisBiotix inventory is a good highlight. although it is difficult to gauge how much of the original stock needs replenishing. That said, given the upward trajectory in subscriptions, any new production run will be self-funding. We know this because the margins are high 70%.

I am sure we can all relax more when we have official data confirming the data providers' claim the estimates are indeed "conservative", and more reliance and less concern on sales blarney, which I doubt is blarney otherwise, they kill their own business, as I have outlined before.

DC,

I don't know if you are familiar with Keto-based dieting. I swapped to a low carb option because carbs bloat me, even OPTI's products which I have been using for three years to good effect. Anyway, my point is that Keto products are very expensive, and even snacks have a premium price tag well beyond anything with SlimBiome inside. My point is that many consumers are willing to pay a premium for products that work. Keto falls into the "fad" bracket, but even so, its a huge market that SlimBiome would fit exceptionally well in.

THG (BUNCH OF IDIOTS - LOMG STORY) have a low-carb option with LeanBiome inside. S the direction is low carb option which is a good direction. Sadly, I do not reward exceptionally poor customer service; there will not be buying any more Myprotien products from THG.

Examples of customer service are winging its way to
James.Pochin @thehutgroup.com
investor.relations @thg.com
viki.tahmasebi @thg.com
thg @powerscourt-group.com

https://www.grandviewresearch.com/industry-analysis/ketogenic-diet-market

Mol,

I'm disappointed not to see SlimBiome in a range of protein bars or alternative "snack" bars, such as keto. I find it odd to this date that the only snack bars with SlimBome as the "intel inside" are OPTI/GoFigure at this rather late stage. It has been over three years unless my grey matter deceives me.

I would have thought either H&B or Optipharm would have produced a snack bar by now. I know Optipharm has a range of snack bars as part of their Optislim range, but as yet, non with SlimBiome inside.

Color,

SBTX will not get an SP rerate off the back of an algorithm that will need confirmation from the Company data. I have a hunch when this will be based on the algorithm data, but until then, it is just a hunch and nothing more.

The data Company claims to provide their data to city investors. If it is as useful as they claim, then it has said value, but at this stage, we don't know if this is sale blarney or has more than a grain of truth. Hence my caution. This is also my main reason for not naming the Company at this stage. Once we know the true value, I will not be as shy. :)

I'll perhaps report in more detail at the end of August. But monthly average sales of AxisBiotix have increased. It's obviously too early to get excited, but there is a clear upward trend.

Hence another jump in sales.

Skid,

Any chance of repeating any of this in English, please? TIA

2. Elric, take it or leave it and steps in the a void left by investor relations as with virtually every AIM company. I pick some things out - in the o'hara interview s it's more what's it said, body language, confidence.
I listen to twin Pete's podcast and I know he gives a lot charity wise, but his views on other issues call his thought process, judgement into question.

Possibly, and in addition to UV barrier, wound care, and additional market penetration through new cosmetic delivery mechanisms.

We will need to play the waiting game until Croda/Sederma are ready to show their hand in an incredibly competitive area.

The tail is not wagging the dog!

I commented on the other side this morning.

SBTX is not just about It's not just about AxisBiotix. IMHO, we will get a primer before any update on the AxisBiotix front. This could be from; Acne probiotic formulation advancement, Croda/Sederma update, or positive news on the oral care study and subsequent commercial agreement(s). I suspect two; toothpaste and another for mouthwash. I expect the board to adopt a strategy to create a healthy competition to develop a consumer product and be the first to market - a hedge if you like. PURE GUESSWORK!

Again, from Croda's statement today, we can see some keywords are replicated in the initial agreement with Croda/SBTX.

- skin active technologies
- Beauty Care is being strengthened to deliver more consistent top-line growth, through sustainable ingredients.
- bio-based and milder surfactants, supported by an exciting pipeline of biotech-based ingredients.

- 2022 also sees the launch of a differentiated retinol anti-aging active; by encapsulating the active, we have improved skin penetration by more than nine times, while creating the most sustainable retinol-containing complex on the market.
END
The latter is the most compelling to me because I suspect they have found a way to enhance retinol by including the skinbiotix lysate. Pure guesswork and nothing more.

RNS 20 November 2019
Under the terms of the agreement, SkinBioTherapeutics' proprietary SkinBiotix(TM) platform will be paired with Croda's expertise in the development and commercialisation of unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market. Sederma, part of Croda International, is a specialist in bioactive ingredients for the cosmetic industry, and will be responsible for developing, manufacturing and commercialising the SkinBiotix(TM) technology. As design and build of the active ingredient is carried out there will be concurrent testing in focussed application areas which will be detailed in further, additional agreements.

Any licensed products resulting from this agreement will be sold to Croda's global portfolio of Personal Care customers. SkinBioTherapeutics will be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership which will be subsequently agreed on successful development of the technology.

Sales and distribution rights are for the cosmetic sector alone, leaving SkinBioTherapeutics to focus on further applications of its technology in other sectors.

Extract from Croda update: "Consumer preference for innovative mineral-based sunscreens saw sales of UV filters grow strongly in North America and Asia."

Extract from SBTX RNS Nov 2017
The in vitro tests, for photo-toxicity "sensitivity to sunlight" and ocular toxicity (effect on eye cells), follow on from the recent first stage cytotoxicity tests, as announced on 3 October 2017

The studies were again conducted by Charles River Laboratories, a Contract Research Organisation (CRO), in accordance with the OECD Principles of Good Laboratory Practice.

In the photo-toxicity test, the testers were looking to determine whether the SkinBiotix(R) technology would become toxic to cells when exposed to UV and visible light. The results showed that SkinBiotix(R) is non-phototoxic.

The second test, for ocular toxicity, was carried out to determine whether SkinBiotix(R) is toxic to eye cells. This involved measuring for two important components which are predictive of irritation, corneal opacity (cloudiness) and permeability (ability to let fluids pass through the eye). The SkinBiotix(R) technology also passed this test.

SkinBioTherapeutics will continue developing the technology towards the three applications in skin care, anti-infection and skin repair.

The oral update is expected ASAP, with paper to follow. Direct from the company and in my last update. https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-0bf

colorblind,

Why are you hoping for good news from Croda next week? It is more likely the next news will be from the results of the oral care study, which concludes this week. I mention this in my waffle on the 26th. https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-0bf

FREE SPONSORED https://twitter.com/LEMMINGINVESTOR/status/1552623439596457990

No you don’t. Copy his pseudonym into the filter tab at the top of the thread. Done, no more drivel.